AbbVie Inc (ABBV)vsKoninklijke Philips NV ADR (PHG)
ABBV
AbbVie Inc
$286.40
-0.14%
HEALTHCARE · Cap: $504.37B
PHG
Koninklijke Philips NV ADR
$27.03
+2.35%
HEALTHCARE · Cap: $26.28B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 264% more annual revenue ($64.39B vs $17.66B). ABBV leads profitability with a 9.8% profit margin vs 6.3%. ABBV appears more attractively valued with a PEG of 0.54. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
PHG
Buy63
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-86.7%
Fair Value
$152.97
Current Price
$286.40
$133.43 premium
Margin of Safety
-55.5%
Fair Value
$20.62
Current Price
$27.03
$6.41 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Earnings expanding 61.4% YoY
Growing faster than its price suggests
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
0.5% revenue growth
Distress zone — elevated risk
6.3% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.54 suggests the stock is reasonably priced for its growth.
Bull Case : PHG
The strongest argument for PHG centers on EPS Growth, PEG Ratio, Price/Book. PEG of 0.76 suggests the stock is reasonably priced for its growth.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 80.6x leaves little room for execution misses.
Bear Case : PHG
The primary concerns for PHG are Revenue Growth, Altman Z-Score, Profit Margin.
Key Dynamics to Monitor
PHG carries more volatility with a beta of 0.92 — expect wider price swings.
ABBV is growing revenue faster at 10.2% — sustainability is the question.
ABBV generates stronger free cash flow (3.1B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (73/100 vs 63/100) and 10.2% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Koninklijke Philips NV ADR
HEALTHCARE · MEDICAL DEVICES · USA
Koninklijke Philips NV is a healthcare technology company in North America, Greater China and internationally. The company is headquartered in Amsterdam, the Netherlands.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?